中国医药
中國醫藥
중국의약
China Medicine
2015年
9期
1322-1324
,共3页
赵坚敏%赵素珍%顾庆%郑萍
趙堅敏%趙素珍%顧慶%鄭萍
조견민%조소진%고경%정평
急性胰腺炎%生长抑素%血小板%消化功能
急性胰腺炎%生長抑素%血小闆%消化功能
급성이선염%생장억소%혈소판%소화공능
Acute pancreatitis%Somatostatin%Platelet%Digestive function
目的 探讨生长抑素对急性胰腺炎患者血小板及消化功能的影响.方法 选择江苏省昆山市第二人民医院201 1年4月至2014年1 1月收治的急性胰腺炎患者76例,根据随机数字表法分为观察组和对照组,各38例.对照组患者给予常规治疗,观察组患者在常规治疗的基础上给予生长抑素(0.1 mg,8h/次,3次/d)治疗,比较治疗1周后2组患者血小板参数[平均血小板体积(MPV)、血小板分布宽度(PDW)、血小板膜蛋白140(GMP-140)阳性血小板百分比]和消化功能指标[血清胰蛋白酶原2(TPG-2)、胰淀粉酶和胰脂肪酶]改善情况.结果 治疗前,2组患者MPV、PDW、GMP-140阳性血小板百分比、TPG-2、胰淀粉酶及胰脂肪酶比较,差异均无统计学意义(均P ＞0.05).治疗1周后,2组患者MPV、PDW、GMP-140阳性血小板百分比、TPG-2、胰淀粉酶及胰脂肪酶均明显低于治疗前[观察组:(10.2±1.0)fl比(13.3±1.1)fl,(13.0±1.2)fl比(16.9±1.3)fl,(8.1±1.1)％比(16.6±1.7)％,(3.7±0.6)μg/L比(65.5±6.5)μg/L,(69±8)U/L比(498 ±52) U/L,(118 ± 15) U/L比(273±32) U/L;对照组:(11.5±1.1)fl比(13.3±1.1)fl,(14.9± 1.2)fl比(16.9±1.4)fl,(10.7±1.2)％比(16.6±1.7)％,(19.8±2.5)μg/L比(65.5 ±6.6)μg/L,(125±11)U/L比(496 ±51)U/L,(173±19) U/L比(273±33) U/L],且观察组明显低于对照组,差异均有统计学意义(均P＜0.05).结论 生长抑素治疗可以有效改善急性胰腺炎患者的微循环状态和消化功能.
目的 探討生長抑素對急性胰腺炎患者血小闆及消化功能的影響.方法 選擇江囌省昆山市第二人民醫院201 1年4月至2014年1 1月收治的急性胰腺炎患者76例,根據隨機數字錶法分為觀察組和對照組,各38例.對照組患者給予常規治療,觀察組患者在常規治療的基礎上給予生長抑素(0.1 mg,8h/次,3次/d)治療,比較治療1週後2組患者血小闆參數[平均血小闆體積(MPV)、血小闆分佈寬度(PDW)、血小闆膜蛋白140(GMP-140)暘性血小闆百分比]和消化功能指標[血清胰蛋白酶原2(TPG-2)、胰澱粉酶和胰脂肪酶]改善情況.結果 治療前,2組患者MPV、PDW、GMP-140暘性血小闆百分比、TPG-2、胰澱粉酶及胰脂肪酶比較,差異均無統計學意義(均P ＞0.05).治療1週後,2組患者MPV、PDW、GMP-140暘性血小闆百分比、TPG-2、胰澱粉酶及胰脂肪酶均明顯低于治療前[觀察組:(10.2±1.0)fl比(13.3±1.1)fl,(13.0±1.2)fl比(16.9±1.3)fl,(8.1±1.1)％比(16.6±1.7)％,(3.7±0.6)μg/L比(65.5±6.5)μg/L,(69±8)U/L比(498 ±52) U/L,(118 ± 15) U/L比(273±32) U/L;對照組:(11.5±1.1)fl比(13.3±1.1)fl,(14.9± 1.2)fl比(16.9±1.4)fl,(10.7±1.2)％比(16.6±1.7)％,(19.8±2.5)μg/L比(65.5 ±6.6)μg/L,(125±11)U/L比(496 ±51)U/L,(173±19) U/L比(273±33) U/L],且觀察組明顯低于對照組,差異均有統計學意義(均P＜0.05).結論 生長抑素治療可以有效改善急性胰腺炎患者的微循環狀態和消化功能.
목적 탐토생장억소대급성이선염환자혈소판급소화공능적영향.방법 선택강소성곤산시제이인민의원201 1년4월지2014년1 1월수치적급성이선염환자76례,근거수궤수자표법분위관찰조화대조조,각38례.대조조환자급여상규치료,관찰조환자재상규치료적기출상급여생장억소(0.1 mg,8h/차,3차/d)치료,비교치료1주후2조환자혈소판삼수[평균혈소판체적(MPV)、혈소판분포관도(PDW)、혈소판막단백140(GMP-140)양성혈소판백분비]화소화공능지표[혈청이단백매원2(TPG-2)、이정분매화이지방매]개선정황.결과 치료전,2조환자MPV、PDW、GMP-140양성혈소판백분비、TPG-2、이정분매급이지방매비교,차이균무통계학의의(균P ＞0.05).치료1주후,2조환자MPV、PDW、GMP-140양성혈소판백분비、TPG-2、이정분매급이지방매균명현저우치료전[관찰조:(10.2±1.0)fl비(13.3±1.1)fl,(13.0±1.2)fl비(16.9±1.3)fl,(8.1±1.1)％비(16.6±1.7)％,(3.7±0.6)μg/L비(65.5±6.5)μg/L,(69±8)U/L비(498 ±52) U/L,(118 ± 15) U/L비(273±32) U/L;대조조:(11.5±1.1)fl비(13.3±1.1)fl,(14.9± 1.2)fl비(16.9±1.4)fl,(10.7±1.2)％비(16.6±1.7)％,(19.8±2.5)μg/L비(65.5 ±6.6)μg/L,(125±11)U/L비(496 ±51)U/L,(173±19) U/L비(273±33) U/L],차관찰조명현저우대조조,차이균유통계학의의(균P＜0.05).결론 생장억소치료가이유효개선급성이선염환자적미순배상태화소화공능.
Objective To explore the effect of somatostatin on platelet and digestive function in patients with acute pancreatitis.Methods Totally 76 cases with acute pancreatitis from April 2011 to November 2014 were enrolled and randomly divided into control group (38 cases) receiving conventional treatment and observation group (38 cases) treated with somatostatin (0.1 mg,8 h/time,3 times/day) on the basis of conventional therapy.Before and 1 week after treatment,the platelet function parameters including mean platelet volume (MPV),platelet distribution width (PDW) and proportion of platelet with granule membrane protein-140 (GMP-140) and digestion related indicators,including trypsinogen-2 (TPG-2),amylopsin,pancrelipase,were measured and compared between the two groups.Results There were no significantly differences regarding MPV,PDW,GMP-140 positive platelet,TPG-2,amylopsin and pancrelipase between the two groups (P ＞ 0.05).After 1 week of treatment,MPV,PDW,GMP-140 positive platelet,TPG-2,amylopsin and pancrelipase were all significantly decreased in observation group [(10.2±1.0) flvs (13.3 ±1.1) fl,(13.0±1.2) fl vs (16.9 ±1.3) fl,(8.1 ±1.1)％ vs (16.6± 1.7)％,(3.7±0.6) μg/L vs (65.5 ±6.5) μg/L,(69 ±8) U/L vs (498 ±52) U/L,(118 ±15) U/L vs (273 ±32) U/L] and control group [(11.5 ±1.1) fl vs (13.3 ± 1.1) fl,(14.9 ±1.2) fl vs (16.9 ± 1.4) fl,(10.7±1.2) ％ vs (16.6±1.7) ％,(19.8 ±2.5) μg/L vs (65.5 ±6.6) μg/L,(125 ± 11) U/L vs (496 ± 51) U/L,(173 ± 19) U/L vs (273 ± 33) U/L]; significant differences were also found between the two groups after treatment (all P ＜ 0.05).Conclusion Somatostatin can effectively improve the microcirculation and digestive function in patients with acute pancreatitis.
